

Additional file 6

Table S5. Multivariate Analysis for Heart V20 and Overall Survival

Variables	HR	95% CI	P value
Model Heart V20/ Mean lung dose	Body mass index (kg/m ²) (≤ 21.3 vs. > 21.3)	1.748	0.889-3.437
	Body surface area (m ²) (≤ 1.65 vs. > 1.65)	1.167	0.584-2.330
	ECOG performance status (0–1 vs. 2–3)	0.237	0.119-0.476
	Stage (I&II vs. III)	0.029	0.004-0.208
	Chemotherapy regimen (F vs. NF)	0.168	0.065-0.434
	Heart volume (ml) (≤ 592 vs. > 592)	0.709	0.428-1.174
	PTV prescribed to 36 Gy (ml) (continuous)	0.997	0.996-0.999
	PTV prescribed to 50 Gy (ml) (continuous)	1.003	1.001-1.005
	Heart V20 (%) (continuous)	1.010	1.001-1.019
Model Heart V20/ Lung V5	Mean lung dose (cGy) (continuous)	1.001	1.000-1.002
	Body mass index (kg/m ²) (≤ 21.3 vs. > 21.3)	1.545	0.796-3.000
	Body surface area (m ²) (≤ 1.65 vs. > 1.65)	1.423	0.734-2.761
	ECOG performance status (0–1 vs. 2–3)	0.266	0.135-0.524
	Stage (I&II vs. III)	0.050	0.008-0.306
	Chemotherapy regimen (F vs. NF)	0.220	0.089-0.544
	Heart volume (ml) (≤ 592 vs. > 592)	0.740	0.446-1.226
	PTV prescribed to 36 Gy (ml) (continuous)	0.998	0.997-1.000
	PTV prescribed to 50 Gy (ml) (continuous)	1.002	1.001-1.004
Model Heart V20/ Lung V10	Heart V20 (%) (continuous)	1.010	1.001-1.020
	Lung V5 (%) (continuous)	1.015	0.988-1.042
	Body mass index (kg/m ²) (≤ 21.3 vs. > 21.3)	1.507	0.779-2.915
	Body surface area (m ²) (≤ 1.65 vs. > 1.65)	1.425	0.735-2.764
	ECOG performance status (0–1 vs. 2–3)	0.258	0.130-0.512
	Stage (I&II vs. III)	0.050	0.008-0.301
	Chemotherapy regimen (F vs. NF)	0.223	0.090-0.555
	Heart volume (ml) (≤ 592 vs. > 592)	0.731	0.439-1.218
	PTV prescribed to 36 Gy (ml) (continuous)	0.998	0.997-1.000

Model Heart V20/ Lung V20	Body mass index (kg/m^2) (≤ 21.3 vs. > 21.3)	1.497	0.776-2.885	0.229
	Body surface area (m^2) (≤ 1.65 vs. > 1.65)	1.357	0.697-2.641	0.370
	ECOG performance status (0–1 vs. 2–3)	0.236	0.116-0.480	0.000
	Stage (I&II vs. III)	0.044	0.007-0.278	0.001
	Chemotherapy regimen (F vs. NF)	0.211	0.084-0.531	0.001
	Heart volume (ml) (≤ 592 vs. > 592)	0.703	0.419-1.177	0.180
	PTV prescribed to 36 Gy (ml) (continuous)	0.998	0.996-1.000	0.016
	PTV prescribed to 50 Gy (ml) (continuous)	1.003	1.001-1.004	0.003
	Heart V20 (%) (continuous)	1.011	1.002-1.020	0.020
Model Heart V20/ Lung V30	Lung V20 (%) (continuous)	1.034	0.980-1.090	0.221
	Body mass index (kg/m^2) (≤ 21.3 vs. > 21.3)	1.513	0.783-2.924	0.218
	Body surface area (m^2) (≤ 1.65 vs. > 1.65)	1.354	0.693-2.642	0.375
	ECOG performance status (0–1 vs. 2–3)	0.234	0.115-0.475	0.000
	Stage (I&II vs. III)	0.043	0.007-0.269	0.001
	Chemotherapy regimen (F vs. NF)	0.222	0.090-0.548	0.001
	Heart volume (ml) (≤ 592 vs. > 592)	0.687	0.408-1.157	0.158
	PTV prescribed to 36 Gy (ml) (continuous)	0.998	0.996-1.000	0.015
	PTV prescribed to 50 Gy (ml) (continuous)	1.003	1.001-1.004	0.002
Model Heart V20/ Lung V40	Heart V20 (%) (continuous)	1.011	1.003-1.020	0.011
	Lung V30 (%) (continuous)	1.041	0.979-1.107	0.198
	Body mass index (kg/m^2) (≤ 21.3 vs. > 21.3)	1.489	0.769-2.884	0.238
	Body surface area (m^2) (≤ 1.65 vs. > 1.65)	1.395	0.717-2.715	0.327
	ECOG performance status (0–1 vs. 2–3)	0.244	0.122-0.488	0.000
	Stage (I&II vs. III)	0.043	0.007-0.269	0.001
	Chemotherapy regimen (F vs. NF)	0.240	0.099-0.584	0.002
	Heart volume (ml) (≤ 592 vs. > 592)	0.691	0.409-1.168	0.168
	PTV prescribed to 36 Gy (ml) (continuous)	0.998	0.996-1.000	0.017
Model Heart V20/ Lung V40	PTV prescribed to 50 Gy (ml) (continuous)	1.003	1.001-1.004	0.003
	Heart V20 (%) (continuous)	1.012	1.003-1.021	0.009
	Lung V40 (%) (continuous)	1.043	0.973-1.119	0.236

Abbreviations: *ECOG* Eastern Cooperative Oncology Group, *F* fluoropyrimidine-based, *NF* not fluoropyrimidine-based, *PTV* planning target volume, *Vx* percentage of the heart volume receiving more than x gray